These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24843581)

  • 1. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Kashiwabara D; Kageyama S; Hotta N
    J Diabetes Investig; 2012 Jun; 3(3):302-8. PubMed ID: 24843581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
    Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Oikawa T; Kageyama S; Hotta N
    J Diabetes Investig; 2014 Feb; 5(1):72-9. PubMed ID: 24843740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
    Terawaki Y; Iwaya C; Nomiyama T; Shimono D; Horikawa T; Fujimura-Tanaka Y; Shigeoka T; Hamanoue N; Motonaga R; Tanabe M; Yanase T; Kawanami D;
    Diabetol Int; 2020 Jul; 11(3):274-282. PubMed ID: 32802709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
    Pan CY; Gao Y; Li GW; Zhu XX; Gao X; Liu X
    Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):304-7. PubMed ID: 19576120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Cardiovascular Safety of Meglitinides.
    Philip J; Fernandez CJ
    Curr Drug Saf; 2021; 16(2):207-216. PubMed ID: 33106149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.
    Kojima Y; Kaga H; Hayashi S; Kitazawa T; Iimura Y; Ohno M; Yoshitsugu M; Fujiwara M; Hiyoshi T
    World J Diabetes; 2013 Feb; 4(1):8-13. PubMed ID: 23493856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
    Landgraf R; Bilo HJ; Müller PG
    Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
    Hanefeld M; Bouter KP; Dickinson S; Guitard C
    Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
    Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
    Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.